New End Points Create Novel Challenges for Health Plans in Oncology Drug Management

James T. Kenney, RPh, MBA

July 2011, Vol 2, No 4 - Commentary

The management of complex oncology drugs in pharmacy and in medical benefits presents unique challenges for all parties who seek cost-effective, positive clinical outcomes for patients with cancer. New therapies are offering the exciting prospect of improved outcomes, prolonged life, and, in some cases, a cure for specific diseases. Targeted oncolytics and pharmacogenomics, which carry the promise of improved likelihood of successful treatment, have become welcome additions to the current standards of care. [ Read More ]